Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yu-Yun Shao

Showing results (11-20 of 114) with videos related to

Pageof 12
Sort By:
Cancer Immunology, Immunotherapy : CII|May 16, 2025
Carry-over effect of immunotherapy in patients with advanced hepatocellular carcinomaChien-Huai Chuang, Ching-Tso Chen, Chih-Hung Hsu, et al.
Journal of Hepatocellular Carcinoma|October 23, 2025
Early PIVKA-II Response Predicts Treatment Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Hepatocellular CarcinomaChing-Tso Chen, Chien-Huai Chuang, Chih-Hung Hsu, et al.
Anticancer Research|August 30, 2022
Expanding Sorafenib Treatment for Hepatocellular Carcinoma Beyond Barcelona Clinic Liver Cancer Stage C Patients: A National StudyChing-Tso Chen, Chih-Hung Hsu, Ann-Lii Cheng, et al.
The Oncologist|January 8, 2011
Increasing incidence of brain metastasis in patients with advanced hepatocellular carcinoma in the era of antiangiogenic targeted therapyYu-Yun Shao, Li-Chun Lu, Ann-Lii Cheng, et al.
Asia-Pacific Journal of Clinical Oncology|June 23, 2010
Hepatic arterial infusion of chemotherapy for advanced hepatocellular carcinomaYu-Yun Shao, Chun-Chieh Huang, Po-Chin Liang, et al.
Journal of Hepatocellular Carcinoma|August 11, 2016
Sorafenib in advanced hepatocellular carcinoma: current status and future perspectivesChih-Hung Hsu, Ying-Chun Shen, Yu-Yun Shao, et al.
Oncology|November 13, 2013
The germline BIM deletion polymorphism is not associated with the treatment efficacy of sorafenib in patients with advanced hepatocellular carcinomaYu-Yun Shao, Yung-Lin Chang, Chung-Yi Huang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 25, 2012
Serum insulin-like growth factor-1 levels predict outcomes of patients with advanced hepatocellular carcinoma receiving antiangiogenic therapyYu-Yun Shao, Chien-Chung Huang, Shiou-Der Lin, et al.
Anticancer Research|February 11, 2014
Clinical characteristics of advanced hepatocellular carcinoma patients with prolonged survival in the era of anti-angiogenic targeted-therapyLi-Chun Lu, Yu-Yun Shao, Soa-Yu Chan, et al.
Journal of Gastroenterology and Hepatology|February 11, 2016
Modified CLIP with objective liver reserve assessment retains prognosis prediction for patients with advanced hepatocellular carcinomaYu-Yun Shao, Tsung-Hao Liu, Ying-Hui Lee, et al.
Pageof 12

Showing results (11-20 of 114) with videos related to

Sort By:
Pageof 12
Cancer Immunology, Immunotherapy : CII|May 16, 2025
Carry-over effect of immunotherapy in patients with advanced hepatocellular carcinomaChien-Huai Chuang, Ching-Tso Chen, Chih-Hung Hsu, et al.
Journal of Hepatocellular Carcinoma|October 23, 2025
Early PIVKA-II Response Predicts Treatment Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Hepatocellular CarcinomaChing-Tso Chen, Chien-Huai Chuang, Chih-Hung Hsu, et al.
Anticancer Research|August 30, 2022
Expanding Sorafenib Treatment for Hepatocellular Carcinoma Beyond Barcelona Clinic Liver Cancer Stage C Patients: A National StudyChing-Tso Chen, Chih-Hung Hsu, Ann-Lii Cheng, et al.
The Oncologist|January 8, 2011
Increasing incidence of brain metastasis in patients with advanced hepatocellular carcinoma in the era of antiangiogenic targeted therapyYu-Yun Shao, Li-Chun Lu, Ann-Lii Cheng, et al.
Asia-Pacific Journal of Clinical Oncology|June 23, 2010
Hepatic arterial infusion of chemotherapy for advanced hepatocellular carcinomaYu-Yun Shao, Chun-Chieh Huang, Po-Chin Liang, et al.
Journal of Hepatocellular Carcinoma|August 11, 2016
Sorafenib in advanced hepatocellular carcinoma: current status and future perspectivesChih-Hung Hsu, Ying-Chun Shen, Yu-Yun Shao, et al.
Oncology|November 13, 2013
The germline BIM deletion polymorphism is not associated with the treatment efficacy of sorafenib in patients with advanced hepatocellular carcinomaYu-Yun Shao, Yung-Lin Chang, Chung-Yi Huang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 25, 2012
Serum insulin-like growth factor-1 levels predict outcomes of patients with advanced hepatocellular carcinoma receiving antiangiogenic therapyYu-Yun Shao, Chien-Chung Huang, Shiou-Der Lin, et al.
Anticancer Research|February 11, 2014
Clinical characteristics of advanced hepatocellular carcinoma patients with prolonged survival in the era of anti-angiogenic targeted-therapyLi-Chun Lu, Yu-Yun Shao, Soa-Yu Chan, et al.
Journal of Gastroenterology and Hepatology|February 11, 2016
Modified CLIP with objective liver reserve assessment retains prognosis prediction for patients with advanced hepatocellular carcinomaYu-Yun Shao, Tsung-Hao Liu, Ying-Hui Lee, et al.
Pageof 12